Research study looking at how well semaglutide works in people suffering from obesity and knee osteoarthritis

Phase 1

• Conditions: Obesity; MedDRA version: 20.0Level: PTClassification code 10029883Term: ObesitySystem Organ Class: 10027433 - Metabolism and nutrition disorders; Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]

• Registration Number: EUCTR2020-000204-11-SE
• Lead Sponsor: ovo Nordisk A/S

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-12-11
• Last Update Posted: 9 October 2023

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 375

Inclusion Criteria

- Male or female, age above or equal to 18 years at the time of signing informed consent
- Body Mass Index (BMI) greater than or equal to 30.0 kg/m^2
- Clinical diagnosis of knee OA (American College of Rheumatology criteria) with moderate radiographic changes (Kellgren-Lawrence (KL) grades 2 or 3) in target knee. Target knee joint is defined as most symptomatic knee at screening. If pain in knees are equal target knee joint will be in the most dominant leg.
- Pain due to knee OA
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 356
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 19

Exclusion Criteria

- Joint replacement in target knee
- Arthroscopy or injections into target knee within last 3 months prior to enrolment
- Active joint disease besides knee OA

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified